FDA.reportPublic FDA data

Application 209356

Type
ANDA
Sponsor
AMNEAL PHARMS LLC

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001SUCRALFATESUCRALFATESUSPENSION;ORAL1GM/10MLNoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
17856-0062SucralfateSucralfate OralATLANTIC BIOLOGICALS CORP.ANDACurrent
17856-0062SucralfateSucralfate OralATLANTIC BIOLOGICALS CORP.ANDACurrent
42291-781SucralfateSucralfate OralAvKAREANDACurrent
42291-781SucralfateSucralfate OralAvKAREANDACurrent
50268-732SucralfateSucralfate OralAvPAKANDACurrent
50268-732SucralfateSucralfate OralAvPAKANDACurrent
50268-745SucralfateSucralfate OralAvPAKANDACurrent
50268-745SucralfateSucralfate OralAvPAKANDACurrent
65162-062SucralfateSucralfate OralAmneal Pharmaceuticals LLCANDACurrent
65162-062SucralfateSucralfate OralAmneal Pharmaceuticals LLCANDACurrent
65162-062SucralfateSucralfate OralAmneal Pharmaceuticals LLCANDACurrent
65162-062SucralfateSucralfate OralAmneal Pharmaceuticals LLCANDACurrent
65162-062SucralfateSucralfate OralAmneal Pharmaceuticals LLCANDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
61135ORIG2020-03-17
62330ORIG2019-12-02